Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
July 10 2023 - 8:00AM
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology
company dedicated to breaking through barriers in gene therapy and
neurology, today announced the appointment of Jacquelyn Fahey
Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more
than 25 years of legal experience spanning in-house roles at
multiple biotechnology and pharmaceutical companies. She most
recently served as CLO, Corporate Secretary, and Compliance Officer
of Jounce Therapeutics, Inc.
“Jacqui’s breadth of expertise across securities, business
development, regulatory, intellectual property, and multiple other
legal disciplines makes her a strong addition to the growing
Voyager team,” said Al Sandrock, M.D., Ph.D., Chief Executive
Officer of Voyager. “In addition to her impressive subject matter
expertise, Jacqui has a strong track record as a leader, and I look
forward to adding her voice to our senior leadership team as we
continue to build upon the momentum we have achieved in unlocking
the potential of genetic medicines in neurology.”
In her most recent role at Jounce Therapeutics, Fahey Sandell
was responsible for all legal matters, including supporting key
license agreements with Gilead and the company’s merger agreement
with Concentra Biosciences, LLC. Prior to joining Jounce, Fahey
Sandell served as Vice President, General Counsel and Company
Secretary at Vericel Corporation, where her achievements included
supporting the launch and commercialization of MACI®, a
biologic/device combination for knee pain. Fahey Sandell previously
held senior positions at Millennium: The Takeda Oncology Company
and Genzyme Corporation, and she has worked at multiple top-tier
law firms. Fahey Sandell holds a B.A. from Duke University and a
J.D. from Boston University School of Law.
“It is rare to have the opportunity in one’s career to help
tackle neurological diseases, which affect so many of our loved
ones, and yet have proven so difficult to treat. I look forward to
playing a key role in Voyager’s continued progress in advancing and
enabling new genetic medicine approaches to diseases of the central
nervous system,” said Fahey Sandell.
About Voyager TherapeuticsVoyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company
dedicated to breaking through barriers in gene therapy and
neurology. The potential of both disciplines has been constrained
by delivery challenges; Voyager is leveraging cutting-edge
expertise in capsid discovery and deep neuropharmacology
capabilities to address these constraints. Voyager’s TRACERTM AAV
capsid discovery platform has generated novel capsids with high
target delivery and blood-brain barrier penetration at low doses,
potentially addressing the narrow therapeutic window associated
with conventional gene therapy delivery vectors. This platform is
fueling alliances with Pfizer Inc., Novartis and Neurocrine
Biosciences as well as multiple programs in Voyager’s own pipeline.
Voyager’s pipeline includes wholly-owned and collaborative
preclinical programs in Alzheimer’s disease, amyotrophic lateral
sclerosis (ALS), Parkinson’s disease, and Friedreich’s Ataxia, with
a focus on validated targets and biomarkers to enable a path to
rapid potential proof-of-biology. For more information,
visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and
TRACER™ is a trademark, of Voyager Therapeutics,
Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 and other federal securities laws. The use of words
such as “may,” “might,” “will,” “would,” “should,” “expect,”
“plan,” “anticipate,” “believe,” “estimate,” “target,” “project,”
“intend,” “future,” “potential,” or “continue,” and other similar
expressions are intended to identify forward-looking
statements.
For example, all statements Voyager makes regarding the timing
of the effective date of the appointment of Fahey Sandell, the
contributions Fahey Sandell may make in her role with the Company,
and the Company’s ability to unlock the potential genetic medicines
in neurology.
All forward-looking statements are based on estimates and
assumptions by Voyager’s management that, although Voyager believes
such forward-looking statements to be reasonable, are inherently
uncertain. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those that Voyager expected. Such risks and uncertainties
include, among others, the ability of Fahey Sandell to commence her
role and to perform her duties successfully; the continued
development by Voyager of its platform technology and pipeline
programs; and the sufficiency of Voyager’s cash resources to fund
its operations and corporate objectives.
These statements are also subject to a number of material risks
and uncertainties that are described in Voyager’s most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as updated by its subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of this press release, and any
forward-looking statement speaks only as of the date on which it
was made. Voyager undertakes no obligation to publicly update or
revise this information or any forward-looking statement, whether
as a result of new information, future events or otherwise, except
as required by law.
Contacts
Investors:Andrew Funderburkafunderburk@kendallir.com
Media: Peg Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2023 to Aug 2024